PainReform Ltd (PRFX) ニュース

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures

PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s...

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PainReform Provides Business Update for the Second Quarter of 2024

Reaches full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy Remains on...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) --  PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...

PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110

PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company...